UroGen Pharma Hits New 52-Week High at $33.72, Up 162.88%

UroGen Pharma has reached a significant milestone by hitting a new 52-week high of USD 33.72 on June 18, 2026. This achievement marks a remarkable performance for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, UroGen Pharma has demonstrated impressive growth, with a performance increase of 162.88%, significantly outpacing the S&P 500's 25.41% gain during the same period. With a market capitalization of USD 836 million, UroGen Pharma continues to establish its position in the competitive biotech landscape. The company's return on equity stands at an impressive 145.53%, indicating strong profitability relative to shareholder equity. However, it is important to note that the company is currently loss-making, as reflected in its price-to-earnings ratio and a dividend yield of 0.00%. The stock's 52-week low was recorded at USD 12.73, highlighting the substantial growth it has experienced over the past year.